Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Phase 3 first-line study of zipalertinib in EGFR exon 20 insertion mutation non-small-cell lung cancer…
News
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023
Initial data from the Phase 1 clinical trial of IMVT-1402 on track for September 2023…
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023
Initial data from the Phase 1 clinical trial of IMVT-1402 on track for September 2023…
Entrada Therapeutics Appoints Gina Chapman to its Board of Directors
Ms. Gina Chapman Ms. Gina Chapman BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) — Entrada Therapeutics,…
Entrada Therapeutics Appoints Gina Chapman to its Board of Directors
Ms. Gina Chapman Ms. Gina Chapman BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) — Entrada Therapeutics,…
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
Initiation cleared for 50 mg cohort in Phase 2 Friedreich’s ataxia (FA) dose exploration trial…
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
Initiation cleared for 50 mg cohort in Phase 2 Friedreich’s ataxia (FA) dose exploration trial…
Altimmune Announces Second Quarter 2023 Financial Results and Provides a Business Update
Top-line 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023 Commenced enrollment…
Altimmune Announces Second Quarter 2023 Financial Results and Provides a Business Update
Top-line 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023 Commenced enrollment…
Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results
Ninth patient dosed in ongoing Phase 1b trial evaluating tegoprubart in patients undergoing kidney transplantation;…
Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results
Ninth patient dosed in ongoing Phase 1b trial evaluating tegoprubart in patients undergoing kidney transplantation;…
Optinose Reports Second Quarter 2023 Financial Results and Operational Updates
Company reports second quarter 2023 XHANCE net revenue of $19.5 million and increases full year…
Optinose Reports Second Quarter 2023 Financial Results and Operational Updates
Company reports second quarter 2023 XHANCE net revenue of $19.5 million and increases full year…
Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
– Received second IND application clearance for CABA-201 in myositis as well as Fast Track…
Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
– Received second IND application clearance for CABA-201 in myositis as well as Fast Track…
TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Presented preliminary Phase 1 clinical data from heme malignancies trial at the ASGCT 26th Annual…
TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Presented preliminary Phase 1 clinical data from heme malignancies trial at the ASGCT 26th Annual…
Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments
Camsirubicin Phase 1b Trial Currently at 5th Dose-Level (650 mg/m2), Generating Encouraging ResultsMNPR-101 Radiopharma Program…
Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments
Camsirubicin Phase 1b Trial Currently at 5th Dose-Level (650 mg/m2), Generating Encouraging ResultsMNPR-101 Radiopharma Program…
Two-year PULSAR Trial Results for Aflibercept 8 mg Demonstrate Durable Vision Gains at Extended Dosing Intervals in Wet Age-related Macular Degeneration
88% of all aflibercept 8 mg patients were on a ≥12-week dosing interval at the…